TEL AVIV, Israel, Nov. 6, 2014 (GLOBE NEWSWIRE) -- Alcobra Ltd. (Nasdaq:ADHD), an emerging pharmaceutical company focused on the development of new medications to help patients with cognitive disorders, including Attention Deficit Hyperactivity Disorder (ADHD) and Fragile X Syndrome, today announced that it will report its financial results for the third quarter of 2014 and will host a corporate update conference call and webcast, on Monday, November 17, 2014 at 8:30am Eastern Time.
Conference Call & Webcast
Monday, November 17 @ 8:30am Eastern Time/5:30am Pacific Time
| Domestic: | 855-469-0611 |
| International: | 484-756-4341 |
| Passcode: | 23967565 |
| Webcast: | http://www.alcobra-pharma.com/indexInvestor.cfm |
| Replays, available through December 1, 2014 | |
| Domestic: | 855-859-2056 |
| International: | 404-537-3406 |
| Passcode: | 23967565 |
About Alcobra Ltd.
Alcobra Ltd. is an emerging pharmaceutical company primarily focused on the development and commercialization of a proprietary drug candidate, MDX, to treat cognitive disorders including Attention Deficit Hyperactivity Disorder (ADHD) and Fragile X Syndrome. MDX has completed multiple Phase II studies and a Phase III study in adults with ADHD. The company is conducting separate Phase IIb trials in pediatric ADHD and Fragile X Syndrome. For more information please visit the Company's website, www.alcobra-pharma.com, the content of which is not incorporated herein by reference.